Streetbeat News

ESPR

Esperion Therapeutics, Inc.

https://www.esperion.com

Industry

Drug Manufacturers - Specialty & Generic

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Open

2.13

Mkt cap

467M

Volume

3.3M

High

2.38

P/E Ratio

-3.54

52-wk high

3.40

Low

2.13

Div yield

N/A

52-wk low

1.15

Esperion presented new exploratory data from the CLEAR Outcomes Trial at the AHA Scientific Sessions 2024, showing that patients with PAD taking NEXLETOL (bempedoic acid) were 36% less likely to experience major adverse limb events compared to placebo.

Portfolio Pulse from

November 18, 2024 | 3:45 pm

Esperion has granted 12,900 restricted stock units to four new employees under its 2017 Inducement Equity Incentive Plan, as per NASDAQ Listing Rule 5635(c)(4).

Portfolio Pulse from

November 08, 2024 | 9:30 pm

Esperion Therapeutics (ESPR) reported a wider-than-expected loss for Q3 2024, with revenues also falling short of estimates. Despite the revenue increase year-over-year, the financial results were disappointing.

Portfolio Pulse from

November 07, 2024 | 5:15 pm

Esperion Therapeutics (ESPR) reported a Q3 loss of $0.15 per share, missing the Zacks Consensus Estimate of a $0.14 loss. This is an improvement from the $0.37 loss per share a year ago.

Portfolio Pulse from

November 07, 2024 | 1:30 pm

Esperion Therapeutics reported a 52% year-over-year increase in total revenue for Q3 2024, reaching $51.6 million. U.S. net product revenue grew by 53% to $31.1 million.

Portfolio Pulse from

November 07, 2024 | 11:15 am

Esperion Therapeutics shares rose following positive data from a study conducted by its European partner, Daiichi Sankyo Europe. The study, part of the MILOS project, provided favorable 2-year follow-up results from the German cohort.